Top-line data from a Phase II study combining Regulus Therapeutics Inc.'s RG-101 with approved direct-acting antiviral drugs for hepatitis C indicate that adding a microRNA therapeutic to a DAA – particularly Gilead Sciences Inc.'s Harvoni – may finally bring the concept of four-week curative treatment for HCV to reality.
On June 7, the La Jolla, Calif.-based biotech unveiled data showing that all patients given a subcutaneous 2 mg/kg dose of RG-101 at day one and day 29, sandwiching four...